DK2403867T3 - Assembly activating protein (aap) og dets anvendelse til fremstilling af parvoviruspartikler hovedsageligt bestående af vp3 - Google Patents
Assembly activating protein (aap) og dets anvendelse til fremstilling af parvoviruspartikler hovedsageligt bestående af vp3 Download PDFInfo
- Publication number
- DK2403867T3 DK2403867T3 DK10708716.5T DK10708716T DK2403867T3 DK 2403867 T3 DK2403867 T3 DK 2403867T3 DK 10708716 T DK10708716 T DK 10708716T DK 2403867 T3 DK2403867 T3 DK 2403867T3
- Authority
- DK
- Denmark
- Prior art keywords
- aap
- manufacturing
- activating protein
- mainly consisting
- particles mainly
- Prior art date
Links
- 241000125945 Protoparvovirus Species 0.000 title 1
- 230000003213 activating effect Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15743609P | 2009-03-04 | 2009-03-04 | |
| US30620510P | 2010-02-19 | 2010-02-19 | |
| PCT/EP2010/001343 WO2010099960A2 (en) | 2009-03-04 | 2010-03-04 | Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essential consisting of vp3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2403867T3 true DK2403867T3 (da) | 2019-08-12 |
Family
ID=42313642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10708716.5T DK2403867T3 (da) | 2009-03-04 | 2010-03-04 | Assembly activating protein (aap) og dets anvendelse til fremstilling af parvoviruspartikler hovedsageligt bestående af vp3 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9464119B2 (OSRAM) |
| EP (1) | EP2403867B1 (OSRAM) |
| JP (2) | JP2012519008A (OSRAM) |
| CN (1) | CN102341406B (OSRAM) |
| BR (1) | BRPI1013364A2 (OSRAM) |
| CA (1) | CA2754335C (OSRAM) |
| DK (1) | DK2403867T3 (OSRAM) |
| ES (1) | ES2742180T3 (OSRAM) |
| MX (2) | MX345729B (OSRAM) |
| PL (1) | PL2403867T3 (OSRAM) |
| PT (1) | PT2403867T (OSRAM) |
| WO (1) | WO2010099960A2 (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2403867B1 (en) | 2009-03-04 | 2019-05-22 | Deutsches Krebsforschungszentrum | Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essential consisting of vp3 |
| WO2011100330A2 (en) * | 2010-02-12 | 2011-08-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for preventing or treating a human parvovirus infection |
| AR082925A1 (es) * | 2010-09-08 | 2013-01-16 | Medigene Ag | Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados |
| RU2487708C1 (ru) * | 2012-03-12 | 2013-07-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГБОУ ВПО УГМА Минздравсоцразвития России) | Способ лечения парвовирусной инфекции в19 у детей раннего возраста |
| TWI775096B (zh) | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| CA2942776C (en) | 2014-03-17 | 2023-01-24 | Adverum Biotechnologies, Inc. | Polyneucleotide cassette and expression vector for expression of a gene in cone cells using truncated m-opsin promoter |
| EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| KR20170096998A (ko) | 2014-11-05 | 2017-08-25 | 보이저 테라퓨틱스, 인크. | 파킨슨병의 치료를 위한 aadc 폴리뉴클레오티드 |
| WO2016077687A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| WO2016077689A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| KR20170137730A (ko) | 2015-03-02 | 2017-12-13 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법 |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| CA2994160C (en) | 2015-07-30 | 2021-08-10 | Massachusetts Eye And Ear Infirmary | Ancestral virus sequences and uses thereof |
| GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| BR112018073472A2 (pt) | 2016-05-18 | 2019-08-27 | Voyager Therapeutics Inc | composições e métodos de tratamento da doença de huntington |
| CA3024448C (en) | 2016-05-18 | 2025-09-09 | Voyager Therapeutics, Inc. | MODULATING POLYNUCLEOTIDES |
| JP2019531787A (ja) | 2016-08-30 | 2019-11-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム |
| WO2018204786A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| SG11201909868YA (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| JP2020530307A (ja) | 2017-06-30 | 2020-10-22 | インティマ・バイオサイエンス，インコーポレーテッド | 遺伝子治療のためのアデノ随伴ウイルスベクター |
| CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| EP3662060A2 (en) | 2017-08-03 | 2020-06-10 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| US20200231986A1 (en) * | 2017-09-29 | 2020-07-23 | Massachusetts Eye And Ear Infirmary | Production of adeno-associated viruses in insect cells |
| CA3075656A1 (en) | 2017-09-29 | 2019-04-04 | Voyager Therapeutics, Inc. | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery |
| WO2019079240A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| EP4454654A3 (en) | 2017-10-16 | 2025-02-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| US20190202866A1 (en) * | 2017-12-22 | 2019-07-04 | William Marsh Rice University | Viral nanoparticles and methods of use thereof |
| EP3527223A1 (en) | 2018-02-16 | 2019-08-21 | 2A Pharma AB | Mutated parvovirus structural protein |
| CN112074295A (zh) | 2018-02-16 | 2020-12-11 | 2A制药公司 | 用于治疗自身免疫性疾病的细小病毒结构蛋白 |
| AU2019227910B2 (en) | 2018-02-28 | 2025-07-17 | The Regents Of The University Of California | A modular system for gene and protein delivery based on AAV |
| US20210147487A1 (en) * | 2018-04-04 | 2021-05-20 | The University Of North Carolina At Chapel Hill | Methods and compositions for engineered assembly activating proteins (eaaps) |
| EP3775266A4 (en) | 2018-04-05 | 2021-06-30 | Massachusetts Eye and Ear Infirmary | METHOD OF MANUFACTURING AND USING COMBINATIONAL BAR-CODED NUCLEIC ACID LIBRARIES WITH DEFINED VARIATION |
| WO2019210267A2 (en) * | 2018-04-27 | 2019-10-31 | Spark Therapeutics, Inc. | Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same |
| JP2021523914A (ja) | 2018-05-15 | 2021-09-09 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | パーキンソン病を治療するための組成物および方法 |
| JP7528066B2 (ja) | 2018-09-28 | 2024-08-05 | ボイジャー セラピューティクス インコーポレイテッド | 操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法 |
| WO2020142236A1 (en) * | 2019-01-02 | 2020-07-09 | Intima Bioscience, Inc. | Modified adeno-associated viral vectors for use in genetic engineering |
| MX2021009305A (es) | 2019-02-04 | 2021-11-04 | Freeline Therapeutics Ltd | Polinucleotidos. |
| CN113728108A (zh) | 2019-02-15 | 2021-11-30 | 桑格摩生物治疗股份有限公司 | 用于生产重组aav的组合物和方法 |
| IL296544A (en) * | 2019-04-12 | 2022-11-01 | Freeline Therapeutics Ltd | Plasmid system |
| WO2021158648A1 (en) * | 2020-02-07 | 2021-08-12 | Vecprobio, Inc. | Recombinant adeno-associated viral vectors in plants |
| US20230374540A1 (en) * | 2020-06-25 | 2023-11-23 | Ferring Ventures Sa | Improved adeno-associated virus gene therapy vectors |
| WO2023083964A1 (en) | 2021-11-11 | 2023-05-19 | 2A Pharma Ab | Parvovirus structural protein against beta- and gamma-hpv |
| WO2024078584A1 (zh) * | 2022-10-13 | 2024-04-18 | 康霖生物科技（杭州）有限公司 | 腺相关病毒的衣壳蛋白编码基因改造方法 |
| CN117126270B (zh) * | 2023-10-25 | 2024-02-13 | 首都儿科研究所 | 一种2型人博卡病毒型别特异性抗体及其应用 |
| WO2025125222A1 (en) | 2023-12-11 | 2025-06-19 | Leukocare Ag | Compositions comprising viruses, viral vectors or virus-like particles |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4168062A (en) | 1977-12-05 | 1979-09-18 | Mccarthy Gerald F | Automated goalie |
| US6027722A (en) * | 1990-10-25 | 2000-02-22 | Nature Technology Corporation | Vectors for gene transfer |
| DE19905501B4 (de) | 1999-02-10 | 2005-05-19 | MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie | Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels |
| US20020052040A1 (en) * | 1999-06-30 | 2002-05-02 | Nicholas Hunt | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
| DE19933288A1 (de) | 1999-07-15 | 2001-01-18 | Medigene Ag | Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung |
| DE19933719A1 (de) | 1999-07-19 | 2001-01-25 | Medigene Ag | Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung |
| JP2001169777A (ja) | 1999-07-30 | 2001-06-26 | Hiroshi Handa | アデノ随伴ウイルスのｖｐ３キャプシド蛋白質からウイルス様粒子を形成する方法 |
| US7638120B2 (en) * | 2000-03-14 | 2009-12-29 | Thomas Jefferson University | High transgene expression of a pseudotyped adeno-associated virus type |
| DE10024334B4 (de) | 2000-05-17 | 2006-06-01 | Medigene Ag | Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat |
| US6962815B2 (en) * | 2001-01-05 | 2005-11-08 | Children's Hopital Inc. | AAV2 vectors and methods |
| US7749492B2 (en) * | 2001-01-05 | 2010-07-06 | Nationwide Children's Hospital, Inc. | AAV vectors and methods |
| WO2003006616A2 (en) * | 2001-07-13 | 2003-01-23 | University Of Iowa Research Foundation | Pseudotyped adeno-associated viruses and uses thereof |
| AU2003295312B2 (en) | 2002-05-01 | 2008-08-14 | University Of Florida Research Foundation, Inc. | Improved rAAV expression systems for genetic modification of specific capsid proteins |
| US20060093589A1 (en) * | 2004-02-19 | 2006-05-04 | Warrington Kenneth H | Vp2-modified raav vector compositions and uses therefor |
| WO2004000220A2 (en) * | 2002-06-21 | 2003-12-31 | Genetix Pharmaceuticals, Inc. | Methods for purifying viral particles for gene therapy |
| EP2012122A1 (en) | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| ES2602610T3 (es) | 2007-05-31 | 2017-02-21 | Medigene Ag | Proteína estructural mutada de un parvovirus |
| EP2403867B1 (en) | 2009-03-04 | 2019-05-22 | Deutsches Krebsforschungszentrum | Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essential consisting of vp3 |
-
2010
- 2010-03-04 EP EP10708716.5A patent/EP2403867B1/en active Active
- 2010-03-04 MX MX2014014365A patent/MX345729B/es unknown
- 2010-03-04 CA CA2754335A patent/CA2754335C/en active Active
- 2010-03-04 PL PL10708716T patent/PL2403867T3/pl unknown
- 2010-03-04 JP JP2011552364A patent/JP2012519008A/ja active Pending
- 2010-03-04 MX MX2011009193A patent/MX2011009193A/es active IP Right Grant
- 2010-03-04 DK DK10708716.5T patent/DK2403867T3/da active
- 2010-03-04 US US13/203,442 patent/US9464119B2/en active Active
- 2010-03-04 ES ES10708716T patent/ES2742180T3/es active Active
- 2010-03-04 WO PCT/EP2010/001343 patent/WO2010099960A2/en not_active Ceased
- 2010-03-04 CN CN201080010540.8A patent/CN102341406B/zh active Active
- 2010-03-04 BR BRPI1013364A patent/BRPI1013364A2/pt not_active Application Discontinuation
- 2010-03-04 PT PT10708716T patent/PT2403867T/pt unknown
-
2015
- 2015-10-09 JP JP2015200962A patent/JP6151328B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-12 US US15/263,072 patent/US10344057B2/en active Active
-
2019
- 2019-05-17 US US16/415,676 patent/US11267847B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011009193A (es) | 2011-12-16 |
| US20200087352A1 (en) | 2020-03-19 |
| CA2754335C (en) | 2019-12-24 |
| PT2403867T (pt) | 2019-08-29 |
| ES2742180T3 (es) | 2020-02-13 |
| WO2010099960A2 (en) | 2010-09-10 |
| BRPI1013364A2 (pt) | 2016-03-29 |
| US20120135022A1 (en) | 2012-05-31 |
| PL2403867T3 (pl) | 2019-12-31 |
| EP2403867A2 (en) | 2012-01-11 |
| CN102341406A (zh) | 2012-02-01 |
| CA2754335A1 (en) | 2010-09-10 |
| US9464119B2 (en) | 2016-10-11 |
| MX345729B (es) | 2017-02-14 |
| CN102341406B (zh) | 2016-06-08 |
| US10344057B2 (en) | 2019-07-09 |
| JP2016063810A (ja) | 2016-04-28 |
| WO2010099960A3 (en) | 2011-01-13 |
| JP6151328B2 (ja) | 2017-06-21 |
| EP2403867B1 (en) | 2019-05-22 |
| US20170226160A1 (en) | 2017-08-10 |
| US11267847B2 (en) | 2022-03-08 |
| JP2012519008A (ja) | 2012-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2403867T3 (da) | Assembly activating protein (aap) og dets anvendelse til fremstilling af parvoviruspartikler hovedsageligt bestående af vp3 | |
| HUS2200051I1 (hu) | Csecsemõmirigy sztrómális limfopoietin megkötésére képes antigén-kötõ fehérjék | |
| DK2475372T4 (da) | Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse | |
| DK2480574T3 (da) | Anti-cd33-antistoffer og deres anvendelse til immunotargeting i behandlingen af cd33-associerede sygdomme | |
| DK3091034T3 (da) | Anti-CD40-antistoffer og anvendelser deraf | |
| DK2913344T3 (da) | Specifikke bindingsproteiner og anvendelser deraf | |
| DE112010001186A5 (de) | Filtermedium und Filterelement | |
| EP2338056A4 (en) | CHEMICAL MODULATORS OF PRO-APOPTOTIC BAX AND BCL-2 POLYPEPTIDES | |
| BRPI0922708A2 (pt) | peptídeos mini-hepcidina e métodos de uso do mesmo | |
| PT2388266E (pt) | Moléculas de fusão e variantes de il-15 | |
| BRPI1009455A2 (pt) | anticorpos anti-c40 e usos dos mesmos | |
| DK2384271T3 (da) | Fremgangsmåde til fremstilling af belagte gummipartikler og belagte gummipartikler | |
| PL2427212T3 (pl) | Przeciwciała anty cd-100 i sposoby ich zastosowania | |
| EP2331573A4 (en) | ANTIBODIES AGAINST HEPATITIS C AND USES THEREOF | |
| ATE531720T1 (de) | Aza-benzofuranylverbindungen und anwendungsverfahren dafür | |
| EP2253009A4 (en) | LOW TEMPERATURE PLASMA PROBE AND METHODS OF USE | |
| BRPI0912198A2 (pt) | anticorpos anti-fn14 e usos dos mesmos | |
| EP2512222A4 (en) | COMBINED USE OF CRY1CA AND CRY1FA PROTEINS FOR INSECTRICITY MANAGEMENT | |
| DK2352509T3 (da) | Hla-g-proteiner og farmaceutiske anvendelser deraf | |
| DK2231091T3 (da) | Absorber og absorberende engangsartikel | |
| BR112012002072A2 (pt) | polipeptídeos de fator ix modificados e usos dos mesmos | |
| EP2209114A4 (en) | ENCODER AND DECODER | |
| EP2066174A4 (en) | COMPOSITIONS CONTAINING ALPHA-1-ANTITRYPSIN AND METHODS OF USE | |
| EP2139325A4 (en) | ANTI-ANGIOGENIC AGENTS AND METHODS OF USE | |
| EP2518030A4 (en) | SILICA GLASS CONTAINING TIO2 |